论文部分内容阅读
为确定 Ketotifen(治疗哮喘新药萨地同每片含Ketotifen 1毫克—译者注)治疗支气管哮喘的疗效,曾进行了实验研究和长期的临床试验。实验研究采用了四种模式:支气管抗原激发试验;吸入组胺;吸入乙酰胆碱;运动诱发哮喘。前三种模式,12名病人每隔一周进行三种吸入激发试验。第一种不用任何药物使其肺活量(VC)和第一秒用力呼气量(FEV_1)至少下降20%。第二种及第三种用 Ketotifen 或其他药物(其他有效药物或安慰剂),采用双盲法试验
In order to determine the efficacy of Ketotifen in the treatment of bronchial asthma with the new asthma drug Salbutamol Ketotifen, experimental studies and long-term clinical trials have been conducted. Four models were used in the experimental study: bronchial antigen challenge test; inhalation of histamine; inhalation of acetylcholine; exercise-induced asthma. In the first three modes, three inhalation challenge trials were performed in 12 patients every other week. The first type of medication reduced the vital capacity (VC) and forced expiratory volume in the first second (FEV_1) by at least 20% without any medication. The second and third with Ketotifen or other drugs (other effective drugs or placebo), using double-blind test